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be considered that donors are taken off the ventilator. There
is some evidence that death from asphyxia causes more
myocardial damage than death from exsanguination.34 Fur-
ther experiments are necessary with respect to the detrimen-
tal effects of anoxia and higher filling pressures to evaluate
the efficiency of our myocardial preservation strategy.
Moreover, the detrimental effects of brain death are not
considered in this experimental model. Possibly, brain death
of the donor could further impair the function of the trans-
planted hearts.
In conclusion, transplantation of ischemically compro-
mised hearts harvested after 30 minutes of normothermic
ischemia is possible in this experimental model without
relevant irreversible damage. Contractility, myocardial per-
fusion, metabolic activity, and histologic damage are com-
parable with those of hearts harvested from beating-heart
donors.
We acknowledge the statistical review by Mr Manfred Ol-
schewski, MSc, Institute of Medical Biometry of the Albert-
Ludwigs-University Freiburg.
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Discussion
Dr Frank W. Sellke (Boston, Mass). You had 2 groups of
animals, is that correct? One you harvested, the control group, and
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you gave them Bretschneider’s cardioplegic solution. The other
one was harvested 30 minutes after the ischemic insult started, and
then you gave them HOE 642 and adenosine. How do you know
that just 30 minutes of ischemia would have a major effect on
cardiac function, and how do you know which of these additives,
if any, has any effect? Shouldn’t you have more groups to have a
valid comparison.
Dr Martin. Yes, that is a good question. We built on experi-
ments we had performed some years ago in an acute model with an
observation time of 2 hours, and there we performed some pilot
studies. We published the results in the European Journal of
Cardio-Thoracic Surgery. We found that by using only crystalloid
cardioplegia, we were not able to wean the hearts from the extra-
corporeal circulation; this was only possible with blood cardiople-
gia. We have introduced, compared with these further experiments,
some additional refinements, and these refinements include the use
of adenosine, which has been investigated by many investigators in
the field of myocardial protection. Adenosine and HOE 642 have
a lot of properties to improve myocardial protection, and we have
given them as an adjunct to the intermittent reperfusions of the
transplanted hearts during implantation. After each anastomosis,
we gave 300 mL of blood cardioplegia.
Dr Henry M. Spotnitz (New York, NY). Can you comment on
whether preservation of the control group was optimal?
Dr Martin. In the control group we used hearts from beating-
heart donors, and they were transplanted in a standard fashion. The
aorta was clamped, the Bretschneider’s cardioplegia was infused,
and the hearts were excised, stored for 4 hours in Bretschneider’s
solution, and transplanted. No reperfusion modifications were per-
formed. The aortic clamp was released after implantation.
Dr Spotnitz. But you did not resuscitate them with the same
protocol you used for the still hearts?
Dr Martin. No, we did not do it because our intention was to
compare these new preservation strategies in NHBDs with the
procedures in hearts transplanted in a clinically standard proce-
dure.
Dr Spotnitz. How would you compare the enzyme release that
you observed in the control group with clinical results?
Dr Martin. We found, in our clinical observations, that
CK-MB is increased after nearly each heart transplantation. I think
you cannot avoid an increase in troponin or CK-MB.
Dr Spotnitz. To a comparable degree?
Dr Martin. Yes. The problem is that we have to use other
enzyme tests than those we use in the clinical arena because the
CK-MB of the pig does not react well with the clinical tests, and
therefore the values are not completely comparable.
Dr Gerald D. Buckberg (Los Angeles, Calif). It is a lovely
study showing the beauty of dealing with reperfusion injury in
hearts that have been dead for basically 30 minutes and trans-
planted. Can you comment on the role of the HOE 642 and calcium
metabolism and leukocytes to make us understand what mecha-
nisms you think are important in your treatment?
Dr Martin. Thank you for this question, Professor Buckberg.
HOE 642 is a sodium-proton exchange inhibitor, and it has been
tested in several in vivo and in vitro models. The principle is that
the sodium-proton exchange is increased during ischemia and
reperfusion because of the increased concentration of protons
within the cell. The sodium-proton exchange inhibitor is activated
to transport these protons to the extracellular space, and therefore
the sodium influx is increased. The consequence of an increased
sodium influx is that this sodium will be transported outside of the
cell by use of the sodium-calcium exchange.
Normally, you have the sodium-potassium exchange, but this
enzyme is adenosine triphosphate dependent, and it will not work
after 1 minute of normothermic ischemia. Because of the lack of
the sodium-potassium exchange, the cell has to use the sodium-
calcium exchange, and the last consequence of this mechanism is
progressive calcium overload of the cell. Calcium deposits in the
mitochondria are responsible for the irreversible myocardial dam-
age. By blocking the sodium-proton exchange in the beginning,
you have more acidosis of the cell, but this is not so deleterious as
a calcium overload.
Dr Sidney Levitsky (Boston, Mass). If that is your hypothesis
for using the sodium-proton exchange inhibitor, which is a valid
hypothesis, shouldn’t you have given the drug before the ischemic
period, when the drug has its greatest effect, rather than after the
fact during the reperfusion period?
Dr Martin. Thank you, Dr Levitsky. That is a very good
question. Of course, several studies have shown that the sodium-
proton exchange inhibitor has the strongest effect if it is given
before ischemia, but we initially tried to perform this transplanta-
tion without special donor pretreatment. This was in accordance to
the ethical considerations, especially in Germany and Europe, that
it is forbidden to treat a potential donor or organ donor only for the
purpose of organ procurement. Now things have changed a bit, and
I think that in the next experiments we should give the sodium-
proton exchange inhibitor before the procurement of the donor
heart.
Dr Paul Grundeman (Utrecht, The Netherlands). In this
model you exsanguinated the animals so the hearts were anoxic in
a fashion that the ventricles actually were not under tension; there
was no wall tension. Now, if you would, let’s say, fibrillate the
animal and you would then take the heart, what would it look like?
I am just asking this question because you might think of the
following clinical situation: you have a person found dead, and 30
minutes after you found this person dead, you want to take the
heart. So this is a different situation. This is sort of artificial.
Dr Martin. Okay, I agree with you, it is of importance which
method to use to induce cardiac arrest. We have chosen this
method because we wanted to use the blood of the donor for the
preparation of blood cardioplegia, but in fact, in the clinical arena
the most common procedure is the controlled NHBDs. These
patients are disconnected from the respirator, and they die as a
result of asphyxia. There are some investigations by other authors
that have shown that asphyxia is more deleterious for the myocar-
dium than exsanguination or other techniques. I think this is a
major limitation of our study that we have not investigated the
influence of asphyxia on the performance of the hearts, and we
should do this in further investigations.
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